Shanghai Pharmaceuticals Holding Co.Ltd(601607) : reply from Shanghai industry (Group) Co., Ltd. on abnormal fluctuation of Shanghai Pharmaceuticals Holding Co.Ltd(601607) stock trading Shanghai Pharmaceuticals Holding Co.Ltd(601607) your inquiry email on abnormal fluctuation of Shanghai Pharmaceuticals Holding Co.Ltd(601607) stock trading sent on March 21 has been received. After verification by the company and consulting the actual controller, we hereby reply that Shanghai Shangshi (Group) Co., Ltd. is the company authorized by our company. Shanghai Tandong Enterprise Consulting Service Co., Ltd., a wholly-owned subsidiary of Shanghai Shangshi (Group) Co., Ltd., as one of the subscribers, participated in the project of non-public offering of A-Shares in Shanghai Pharmaceuticals Holding Co.Ltd(601607) 2021. At present, the project has been approved by the issuance Audit Committee of the CSRC. In addition, the company has no major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset divestiture, asset injection, share repurchase, bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major matters related to Shanghai Pharmaceuticals Holding Co.Ltd(601607) of the company. We hereby reply that your company is requested to timely fulfill the obligation of information disclosure in accordance with the requirements of the regulatory authorities
© China Stock Market News